Cátedra de Clínica Médica – Facultad de Ciencias Médicas – Universidad Nacional de Rosario

Referencias

1- Messerli FH, Williams B, Ritz E. Essential hypertension. The Lancet. August 18, 2.007; 370(9587):591-603.

2- Doval HC, Tajer CD. Evidencias en Cardiología IV. De los ensayos clínicos a las conductas terapeúticas. Ed. CEDIC, 2.005.

3- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).  JAMA. 2000 Apr 19;283(15):1967-75.

4- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981-97.

5- Stevo Julius. The ALLHAT study: if you believe in evidence-based medicine, stick to it! Journal of Hypertension. 2003, 21:453–454

6- Appel LJ. The verdict from ALLHAT–thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2.002, December 18;288(23):3039-42.

7- Peter C. Austin, Muhammad M. Mamdani, Karen Tu, Merrick Zwarenstein. Changes in Prescribing Patterns Following Publication of the ALLHAT Trial. JAMA, January 7, 2004—Vol 291, No. 1.

8- The Seventh Report of the Join National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2.003; 289: 2560-2572.

9- Jay I. Meltzer. A clinical specialist in hypertension critiques JNC 7. American journal of hypertension. 2005 July; 18(7):894-898

10- Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ, for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. The New England Journal of Medicine. 2003 February  13; 348(7):583-92.

11- Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet. 2007 Jan 20;369(9557):201-7.

12- Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004,30,487-496.

13- Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. May 21 2003; 289(19):2534-44.

14- Andraws R, Brown DL Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). The American journal of cardiology. 2007 Apr 1;99(7):1006-12. Epub 2007 Feb 16.

15- Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. Journal of Hypertension.  2006, January 24:3–10.

16- Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of the American College of Cardiology. September 6, 2.005

17- Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. The American journal of cardiology. October 15, 2.007

18- Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiology and Drug Safety. 2007 Sep;16(9):979-87.

19- Beevers DG. The end of beta blockers for uncomplicated hypertension? The Lancet. 2005 Oct 29-Nov 4;366(9496):1510-2.     

20- Simon KH Lam, Andrew Owen. Correspondence. Incident diabetes in clinical trials of antihypertensive drugs. The Lancet  2007; 369: 1513-1514.

21- GD Johnston. Correspondence. Incident diabetes in clinical trials of antihypertensive drugs. The Lancet  2007; 369:1514.

22- Cooper ME, Tikellis C, Thomas MC. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 2006 Mar;24(1):S57-63.

23- Scheen AJ.  Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms.  Diabetes Metab 2004,30,498-505.

24- Carter BL, Basile J. Development of diabetes with thiazide diuretics: the potassium issue. Journal of clinical hypertension (Greenwich, Conn.). November 2005; 7(11):638-40.

25- G. Mancia The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol (2005) 42:S17–S25.

26- Franz H. Messerlia, Ehud Grossmanb and Gastone Leonettic. Antihypertensive therapy and new onset diabetes. Journal of Hypertension 2004, 22:1845–1847

27- Nilsson PM, Cifkova R, Kjeldsen SE, Mancia G. Update on hypertension management: Prevention of type 2 diabetes mellitus with antihypertensive drugs.  European Society of Hypertension Scientific Newsletter. 2006 December 24(12): 2478-82.

28- Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hipertensión. May, 2.004

29- Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. Journal of hypertension. June 2.007; 25(6):1311-7.

30- Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. British Medical Journal. 2003 Mar 29;326(7391):681

31- Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. The New England Journal of Medicine. 2001 Nov 1;345(18):1291-7.

32- Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. The American journal of cardiology. 2005 January 1;95(1):29-35.

33- Alberto Zanchetti. Evidence-based medicine in hypertension: what type of evidence? Journal of Hypertension 2005, 23:1113–1120.

34- Williams B. Evolution of hypertensive disease: a revolution in guidelines. The Lancet. July 1 2006; 368(9529):6-8

35- Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. The Lancet. 2006 Aug 12;368(9535):555-6.

36- Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, Pocock S; ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). The Lancet. 2005, September 10-16;366(9489):907-13.

37- Jan A Staessen, Willem H Birkenhäger. Evidence that new antihypertensives are superior to older drugs. The Lancet. September 2.005.; 10-16;366(9489):869-71.

38- McMurray JJV.  ACE Inhibitors in Cardiovascular Disease — Unbeatable? Editorial. N Engl J Med 358;15:1615-1616.

39- The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.